本页面由Tiger Trade Technology Pte. Ltd.提供服务

Caris Life Sciences, Inc.

24.04
+0.01000.04%
盘前24.040.00000.00%08:56 EDT
成交量:262.92万
成交额:6,311.19万
市值:67.83亿
市盈率:64.62
高:24.68
开:23.20
低:23.20
收:24.03
52周最高:34.75
52周最低:14.19
股本:2.82亿
流通股本:1.16亿
量比:0.54
换手率:2.27%
股息:- -
股息率:- -
每股收益(TTM):0.3720
每股收益(LYR):-3.2200
净资产收益率:20.13%
总资产收益率:8.77%
市净率:11.46
市盈率(LYR):-7.47

数据加载中...

2025/11/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/11/05

重要事件披露

Form 8-K - Current report
2025/10/30

重要事件披露

Form 8-K - Current report
2025/08/13

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/08/13

重要事件披露

Form 8-K - Current report
2025/06/20

重要事件披露

Form 8-K - Current report
2025/06/18

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/06/16

[修订]招股说明书

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2025/06/14

SEC问询函

Form CORRESP - Correspondence
2025/06/14

SEC问询函

Form CORRESP - Correspondence
2025/06/09

[修订]招股说明书

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2025/05/24

招股说明书

Form S-1 - General form for registration of securities under the Securities Act of 1933
2021/06/29

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/06/21

重要事件披露

8-K - Current report
2021/06/08

重要事件披露

8-K - Current report
2021/05/26

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/04/30

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2021/04/30

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/04/29

重要事件披露

8-K - Current report
2021/03/01

年度报告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]